Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Gopal, Poornima ^a   Reynaert, Niki L ^a   Scheijen, Jean L J M ^a   Schalkwijk, Casper G ^a   Franssen, Frits M E ^b   Wouters, Emiel F M ^a,b   Rutten, Erica P A ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Centre of Expertise for Chronic Organ Failure   (Netherlands)

Author keywords

COPD; esRAGE; FEV1; SRAGE

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CARBON MONOXIDE; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PENTOSIDINE; TRIACYLGLYCEROL; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

ADULT; ARTICLE; AUTOANALYZER; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG FLOW VOLUME CURVE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXYGEN THERAPY; RESPIRATORY FAILURE; SMOKING; SPIROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; COMPARATIVE STUDY; LUNG; METABOLISM; PATHOLOGY;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, IMMUNOLOGIC;

EID: 84895542636     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-24     Document Type: Article

References (35)

1. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011, 12:37. 10.1186/1465-9921-12-37, 3072955, 21450080.
2. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Crim C, Duvoix A, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013, 1:129-136. 10.1016/S2213-2600(13)70006-7, 24429093.
3. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267:14998-15004.
4. Kumano-Kuramochi M, Ohnishi-Kameyama M, Xie Q, Niimi S, Kubota F, Komba S, Machida S. Minimum stable structure of the receptor for advanced glycation end product possesses multi ligand binding ability. Biochem Biophys Res Commun 2009, 386:130-134. 10.1016/j.bbrc.2009.05.142, 19501570.
5. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008, 22:1572-1580.
6. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727. 10.1096/fj.08-109033, 18603587.
7. Yamakawa N, Uchida T, Matthay MA, Makita K. Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011, 300:L516-L525. 10.1152/ajplung.00118.2010, 3075094, 21257730.
8. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000, 275:25781-25790. 10.1074/jbc.M001235200, 10829018.
9. Gopal P, Reynaert NL, Scheijen JL, Engelen L, Schalkwijk CG, Franssen FM, Wouters EF, Rutten EP. Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. Euro Resp J 2014, 43(2):430-438.
10. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011, 37:516-522. 10.1183/09031936.00029310, 20595148.
11. Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One 2012, 7:e38629. 10.1371/journal.pone.0038629, 3373533, 22701684.
12. Wu L, Ma L, Nicholson LF, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2011, 105:329-336. 10.1016/j.rmed.2010.11.001, 21112201.
13. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, Wark PA. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012, 39:721-729. 10.1183/09031936.00022011, 21920897.
14. Gelb AF, Gold WM, Wright RR, Bruch HR, Nadel JA. Physiologic diagnosis of subclinical emphysema. Am Rev Respir Dis 1973, 107:50-63.
15. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
16. Thurlbeck WM. A pathologist looks at respiratory failure due to obstructive lung disease. Chest 1970, 58(2):408+.
17. Clausen JL, Coates AL, Quanjer PH. Measurement of lung volumes in humans: review and recommendations from an ATS/ERS workshop. Eur Respir J 1997, 10:1205-1206. 10.1183/09031936.97.10061205, 9192917.
18. Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, Van Greevenbroek MM, van der Kallen CJ, Dekker JM, Nijpels G, Stehouwer CD, Schalkwijk CG. Plasma levels of advanced glycation endproducts N{epsilon}-(carboxymethyl)lysine, N{epsilon}-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the HOORN and CODAM studies. J Clin Endocrinol Metab 2013, 98:E1369-E1373. 10.1210/jc.2013-1068, 23780372.
19. Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:610-614. 10.1016/j.jchromb.2009.01.022, 19188098.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
21. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008, 283:35507-35516. 10.1074/jbc.M806948200, 18952609.
22. Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S, Kawakami Y. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 1999, 159:1985-1991. 10.1164/ajrccm.159.6.9809043, 10351949.
23. Finlay GA, Russell KJ, McMahon KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997, 52:502-506. 10.1136/thx.52.6.502, 1758576, 9227714.
24. Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, Masuda M, Itoh H. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005, 25:885-890. 10.1183/09031936.05.00092804, 15863647.
25. Gaens KH, Ferreira I, van der Kallen CJ, Van Greevenbroek MM, Blaak EE, Feskens EJ, Dekker JM, Nijpels G, Heine RJ, Hart LM T, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009, 94:5174-5180. 10.1210/jc.2009-1067, 19890027.
26. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2013, 188(8):948-957. 10.1164/rccm.201302-0247OC, 23947473.
27. Peng WH, Lu L, Wang LJ, Yan XX, Chen QJ, Zhang Q, Zhang RY, Shen WF. RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. Arch Med Res 2009, 40:393-398. 10.1016/j.arcmed.2009.06.008, 19766904.
28. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181:917-927. 10.1164/rccm.200903-0340OC, 20133931.
29. Boschetto P, Campo I, Stendardo M. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest 2013, 43:562-569. 10.1111/eci.12079, 23590548.
30. Gopal P, Rutten EP, Dentener MA, Wouters EF, Reynaert NL. Decreased plasma sRAGE levels in COPD: influence of oxygen therapy. Eur J Clin Invest 2012, 42:807-814. 10.1111/j.1365-2362.2012.02646.x, 22288943.
31. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with ager genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:948-957. 10.1164/rccm.201302-0247OC, 23947473.
32. Hou C, Zhao H, Liu L, Li W, Zhou X, Lv Y, Shen X, Liang Z, Cai S, Zou F. High mobility group protein B1 (HMGB1) in Asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med 2011, 17:807-815. 3146613, 21380479.
33. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl 2007, S17:26.
34. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005, 18:1385-1396. 10.1038/modpathol.3800450, 15933755.
35. Koyama H, Shoji T, Fukumoto S, Shinohara K, Emoto M, Mori K, Tahara H, Ishimura E, Kakiya R, Tabata T, et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 2007, 27:147-153. 10.1161/01.ATV.0000251502.88818.4b, 17082489.